In addition, in Checkmate 227, a phase III NSCLC trial, patients with high TMB had significant enhancements in PFS after nivolumab and ipilimumab treatment in combination with SOC chemotherapy in comparison to patients with positive and negative expression of PD-L1 treated with SOC chemotherapy [95]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.